Efficacy and safety of fixed ‐dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double‐blind, controlled, phase 3 trial

Diabetes, Obesity and Metabolism, EarlyView.

Source: Diabetes, Obesity and Metabolism - September 5, 2018 Category: Endocrinology Authors: Ji Cheol Bae MD , Kyung Wan Min MD , Yong Hyun Kim MD , Kyoung ‐Ah Kim MD , Eun‐Gyoung Hong MD , Cheol‐Young Park MD , Song Han MS , Bong‐Soo Cha MD Source Type: research